Market Research Report
Down Syndrome - Epidemiology Forecast to 2030
|Published by||DelveInsight Business Research LLP||Product code||968107|
|Published||Pre-Order||Content info||94 Pages
Delivery time: 2-10 business days
|Down Syndrome - Epidemiology Forecast to 2030|
|Published: Pre-Order||Content info: 94 Pages||
DelveInsight's 'Down syndrome (DS) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Down syndrome, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Down syndrome (DS) Disease Understanding
Down syndrome (DS) is a congenital disability with substantial medical and social costs caused by trisomy of whole or part of chromosome 21. It is the most prevalent genetic disease worldwide and the common genetic cause of intellectual disabilities. Generally, there are three cytogenetic forms of Down syndrome: free trisomy 21, mosaic trisomy 21, and Robertsonian translocation trisomy 21.
Regardless of the type of Down syndrome a person may have a critical portion of chromosome 21 present in all or some of their cells. This additional genetic material alters the course of development and causes the characteristics associated with Down syndrome.
Delayed development and behavioral problems are often reported in children with Down syndrome. Affected individuals can have growth problems, which might affect their speech and language development later and more slowly than. Behavioral issues can include attention problems, obsessive/compulsive behavior, and stubbornness, or tantrums. A small percentage of people with Down syndrome may also be diagnosed with developmental conditions called autism spectrum disorders, which affect communication and social interaction.
The cause of the extra full or partial chromosome is still unknown. Maternal age is the only factor that has been linked to an increased chance of having a baby with Down syndrome resulting from nondisjunction or mosaicism. Prenatal and postnatal testing has become commonly used to diagnose different cases presenting the same pathology. Early clinical diagnosis is vital for patient prognosis.
The Down syndrome epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Down syndrome epidemiology segmented as the total diagnosed prevalent cases of Down syndrome, type-specific diagnosed prevalent population of Down syndrome, gender-specific diagnosed prevalent population of down syndrome, age-specific diagnosed prevalent population of Down syndrome and diagnosed prevalent population of down syndrome by clinical manifestation. The report includes the Prevalent scenario of Down syndrome symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
The epidemiology segment also provides the Down syndrome (DS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total diagnosed prevalent population of Down Syndrome Associated in the 7MM countries estimated to be 699,750 cases in 2017.
DelveInsight interviews KOLs and obtain SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
The Down syndrome (DS) Epidemiology report will allow the user to:
Study Period: 2017-2030
In the US, DS birth prevalence was estimated by de Graaf et al. (n.d.) at 12.6/10,000 (or 1 in 792) as of 2010. However, only a few studies have estimated US population prevalence. Two previous US studies targeted the age group 0-19 years. For this age group, Shin et al. (n.d.) estimated the population prevalence of 10.3/ 10,000 (or 1 in 971) as of 2002. Besser et al. (n.d.) estimated the prevalence at 8.3/10,000 (or 1 in 1,205) as of 2003.